scholarly journals 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

2020 ◽  
Vol 7 (10) ◽  
pp. e724-e736 ◽  
Author(s):  
Courtney D DiNardo ◽  
Abhishek Maiti ◽  
Caitlin R Rausch ◽  
Naveen Pemmaraju ◽  
Kiran Naqvi ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Intensive Chemotherapy ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Single Centre ◽  
Phase 2 Trial ◽  
Acute Myeloid

scholarly journals Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

2019 ◽  
Vol 6 (1) ◽  
pp. e29-e37 ◽  
Author(s):  
Nicholas J Short ◽  
Hagop M Kantarjian ◽  
Sanam Loghavi ◽  
Xuelin Huang ◽  
Wei Qiao ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Older Patients ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Phase 2 Trial ◽  
Acute Myeloid

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial

2020 ◽  
Vol 7 (2) ◽  
pp. e122-e133 ◽  
Author(s):  
Andrew M Brunner ◽  
Traci M Blonquist ◽  
Daniel J DeAngelo ◽  
Malgorzata McMasters ◽  
Geoffrey Fell ◽  
...  
Keyword(s):  
High Risk ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Phase 2 ◽  
Phase 2 Trial ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document